| Push Therapy Llc | |
|
2111 University Park Dr Ste 400 Okemos MI 48864-6907 | |
| (517) 258-0228 | |
| Not Available |
| Full Name | Push Therapy Llc |
|---|---|
| Speciality | Social Worker |
| Location | 2111 University Park Dr Ste 400, Okemos, Michigan |
| Authorized Official Name and Position | Mary Beth Houpt (CREDENTIALING) |
| Authorized Official Contact | 5176769797 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Push Therapy Llc Po Box 10 Mason MI 48854-0010 Ph: () - | Push Therapy Llc 2111 University Park Dr Ste 400 Okemos MI 48864-6907 Ph: (517) 258-0228 |
| NPI Number | 1023720117 |
|---|---|
| Provider Enumeration Date | 12/20/2022 |
| Last Update Date | 12/20/2022 |
| Certification Date | 12/20/2022 |
| Medicare PECOS PAC ID | 6709256241 |
|---|---|
| Medicare Enrollment ID | O20221228001297 |
News Archive
Using a simple urine test alongside routine imaging for patients with adrenal masses could speed up adrenal cancer diagnosis, improving patient's prognosis and reducing the need for invasive diagnostic procedures, a new multi-centre study published in The Lancet Diabetes & Endocrinology has found.
Should germline genetic testing be offered to all patients with breast cancer? The American College of Medical Genetics and Genomics addresses this important question in a new statement published in Genetics in Medicine, "Points to Consider: Is There Evidence to Support BRCA1/2 and Other Inherited Breast Cancer Genetic Testing for All Breast Cancer Patients? A Statement of the American College of Medical Genetics and Genomics."
A new approach to microscopy is opening up the wonders of the molecular world, allowing researchers to examine organic molecules and delicate crystals as they grow, atom by atom. Dr Andrew Humhpris, co-founder of the original technology and now Chief Technology Officer of Infinitesima, explains how this University spin-out has turned into a leading-edge company.
Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, was granted Fast Track designation by the U.S. Food and Drug Administration for perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of refractory advanced colorectal cancer.
› Verified 9 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023720117 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 104100000X | Social Worker | (* (Not Available)) | Primary |
| Provider Name | Dominique Prince |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1407209935 PECOS PAC ID: 1951644541 Enrollment ID: I20190522002869 |
News Archive
Using a simple urine test alongside routine imaging for patients with adrenal masses could speed up adrenal cancer diagnosis, improving patient's prognosis and reducing the need for invasive diagnostic procedures, a new multi-centre study published in The Lancet Diabetes & Endocrinology has found.
Should germline genetic testing be offered to all patients with breast cancer? The American College of Medical Genetics and Genomics addresses this important question in a new statement published in Genetics in Medicine, "Points to Consider: Is There Evidence to Support BRCA1/2 and Other Inherited Breast Cancer Genetic Testing for All Breast Cancer Patients? A Statement of the American College of Medical Genetics and Genomics."
A new approach to microscopy is opening up the wonders of the molecular world, allowing researchers to examine organic molecules and delicate crystals as they grow, atom by atom. Dr Andrew Humhpris, co-founder of the original technology and now Chief Technology Officer of Infinitesima, explains how this University spin-out has turned into a leading-edge company.
Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, was granted Fast Track designation by the U.S. Food and Drug Administration for perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of refractory advanced colorectal cancer.
› Verified 9 days ago
News Archive
Using a simple urine test alongside routine imaging for patients with adrenal masses could speed up adrenal cancer diagnosis, improving patient's prognosis and reducing the need for invasive diagnostic procedures, a new multi-centre study published in The Lancet Diabetes & Endocrinology has found.
Should germline genetic testing be offered to all patients with breast cancer? The American College of Medical Genetics and Genomics addresses this important question in a new statement published in Genetics in Medicine, "Points to Consider: Is There Evidence to Support BRCA1/2 and Other Inherited Breast Cancer Genetic Testing for All Breast Cancer Patients? A Statement of the American College of Medical Genetics and Genomics."
A new approach to microscopy is opening up the wonders of the molecular world, allowing researchers to examine organic molecules and delicate crystals as they grow, atom by atom. Dr Andrew Humhpris, co-founder of the original technology and now Chief Technology Officer of Infinitesima, explains how this University spin-out has turned into a leading-edge company.
Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, was granted Fast Track designation by the U.S. Food and Drug Administration for perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of refractory advanced colorectal cancer.
› Verified 9 days ago
Shawn Johnson, Ph.d., Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 4111 Okemos Rd Ste 104, Okemos, MI 48864 Phone: 517-347-4755 | |
Gilbert Counseling Services Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 4084 Okemos Rd, Okemos, MI 48864 Phone: 517-347-4848 | |
Msu Health Care Inc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1600 W Grand River Ave Ste 2, Okemos, MI 48864 Phone: 517-349-5796 Fax: 517-349-5796 | |
Dr Lori Naughton Psy D Pc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 1745 Hamilton Rd, #325, Okemos, MI 48864 Phone: 517-676-9788 Fax: 517-676-3438 | |
Envision Therapy Services, Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 1745 Hamilton Rd Ste 355, Okemos, MI 48864 Phone: 517-721-1244 | |
Integrity Counseling Services Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 4747 Okemos Rd, Okemos, MI 48864 Phone: 517-347-0988 Fax: 517-349-3755 |